Stay sharp with the latest research in Cardiology and heart failure with Smartest Doc. Canagliflozin improves outcomes in patients with type 2 diabetes and CKD regardless of the presence of heart failure. Adding ivabradine to standard therapies improves cardiac function in patients with chronic heart failure. Soluble ST2 and catestatin levels predict in-hospital mortality in patients with acute worsening of heart failure. RV strain helps predict outcomes in patients with heart failure and preserved ejection fraction. Lipid profiling may capture preclinical molecular alterations that predispose for incident HF. Ischemic heart disease adversely impacts the clinical course of HFpEF. Catheter ablation of AF improves outcomes in patients with HF. Frailty is highly prevalent in HFrEF. Methamphetamine use is associated with systolic dysfunction. Cardiac fibrosis is increased in heart failure. CHF hospitalization in patients with AF is a poor prognostic marker. Empagliflozin improves heart failure outcomes across the range of kidney function. Galectin-3 levels are not associated with risk of incident HF in patients with chronic kidney disease. Heart failure risk from systemic lupus erythematosus is greatest at younger ages. A history of prior MI is tied to a greater risk of CV death in patients with heart failure and preserved ejection fraction. HF risk scores have comparable performance in men and women. Hypothyroidism doesn't affect mortality risk in patients receiving cardiac resynchronization therapy for heart failure. Failure of noninvasive ventilation increases in the risk of in-hospital mortality in patients with acute heart failure. A smoking history worsens CV outcomes in patients with heart failure and reduced, but not preserved, ejection fraction. Sacubitril-valsartan is superior to ACE-inhibitors and ARBs for patients with heart failure. LV hypertrophy on ECG predicts heart failure hospitalization in middle-age women but not men. The coexistence of multiple frailty domains is common in elderly patients hospitalized with heart failure. Mortality is higher among patients with advanced heart failure living in rural vs urban areas. Soluble ST2 and catestatin levels predict in-hospital mortality in patients with acute worsening of heart failure. RV strain helps predict outcomes in patients with heart failure and preserved ejection fraction. The urinary proteomic classifier HF1 performs as well as BNP for the diagnosis of heart failure. Methotrexate lowers heart failure risk in patients with rheumatoid arthritis. High levels of parathyroid hormone and fibroblast growth factor-23 predict incident heart failure. Statins reduce neurological events in advanced heart failure patients implanted with LV assist systems. A history of prior MI is tied to a greater risk of CV death in patients with heart failure and preserved ejection fraction. Source
